Paul E. Kelly Net Worth & Insider Trades

Paul E. Kelly - Director, Relmada Therapeutics, Inc

As of January 5, 2022

What is Paul E. Kelly's Net Worth?

The current estimated net worth of Relmada Therapeutics, Inc's Director, Paul E. Kelly, is estimated to be about $10.13M . Paul E. Kelly owns about 167,295 units of Relmada Therapeutics, Inc common stock. In the last 7 years at Relmada Therapeutics, Inc, Paul E. Kelly has sold an estimated value of $7.31M worth.

What is Paul E. Kelly's Past Insider Trading?

Paul E. Kelly's largest purchase order was 373,483 units , worth over $295.91K on October 19, 2018. Paul E. Kelly's largest sale order was 4,085 units , worth over $6.46M on January 26, 2021. In total, Paul E. Kelly has made about 19 transactions over 7 years of their time at Relmada Therapeutics, Inc. Paul E. Kelly usually trades in December, October and February, with the busiest year in 2021. The most recent transaction was a sale order of 5,000 units , worth over $178.55K on March 11, 2021.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What is Paul E. Kelly's' Mailing Address?

  • Mailing address is 300 East 56th Street, Apt 19e New York, NY 10022 NY

What are Relmada Therapeutics, Inc's Past Insider Trades?

Relmada Therapeutics, Inc's most recent insider trade came on July 5, 2022 by Sergio Traversa who sold 29,767 units worth $559.58K . In the last 7 years, insiders at Relmada Therapeutics, Inc have sold an estimated value of $13.8M and bought an estimated value of $4.05M worth of shares. Insider trading is most common in December, with the busiest year in 2021. The most active traders at the company are Charles J Casamento, Director,  Paul Kelly, Director,  and Sergio Traversa, Chief Executive Officer .

RELMADA THERAPEUTICS, INC. Insider Trades

Date Range: All Time
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1